	US 12,077,599 B2
	Anti-ROS1 antibody and use thereof
Junho Chung, Seongnam-si (KR); Eugene C. Yi, Seoul (KR); Ji Eun Kim, Seoul (KR); Hwa Kyoung Lee, Seoul (KR); Junyeong Jin, Gwacheon-si (KR); Jong Bae Park, Goyang-si (KR); and Hyori Kim, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NATIONAL CANCER CENTER, Goyang-si (KR); and THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR)
Appl. No. 16/767,245
Filed by Seoul National University R&DB Foundation, Seoul (KR); NATIONAL CANCER CENTER, Goyang-si (KR); THE ASAN FOUNDATION, Seoul (KR); and University of Ulsan Foundation For Industry Cooperation, Ulsan (KR)
PCT Filed Mar. 6, 2018, PCT No. PCT/KR2018/002655 § 371(c)(1), (2) Date May 27, 2020, PCT Pub. No. WO2019/107671, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/591,974, filed on Nov. 29, 2017.
Prior Publication US 2023/0242670 A1, Aug. 3, 2023
Int. Cl. C07K 16/40 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/40 (2013.01) [G01N 33/57423 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

12 Claims

1. An anti-ROS1 antibody or antigen-binding fragment thereof, characterized by binding to a region comprising SEQ ID NO: 11 or SEQ ID NO: 10, in the 39th to 56th region of ROS1 protein (SEQ ID NO: 15), and comprising the following complementarity determining regions (CDRs):

LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 (SGGSYGYG),

LCDR2 comprising the amino acid sequence of SEQ ID NO: 2 (DNTNRPS),

LCDR3 comprising the amino acid sequence of SEQ ID NO: 3 (GSADSSSIAT),

HCDR1 comprising the amino acid sequence of SEQ ID NO: 4 (GFSFSDRGMH),

HCDR2 comprising the amino acid sequence of SEQ ID NO: 5 (ISGDGYITHYGAAVKG), and

HCDR3 comprising the amino acid sequence of SEQ ID NO: 6 (KGGGNIDA) or SEQ ID NO: 13 (GGGGNIDA).